PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation

Brachytherapy

Volumn 9, Issue 2, 2010, Pages 137-144

  McGrath, Samuel D ^a   Antonucci, J Vito ^a   Fitch, Dwight L ^a   Ghilezan, Michel ^a   Gustafson, Gary S ^a   Vicini, Frank A ^a   Martinez, Alvaro A ^a   Kestin, Larry L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Androgen deprivation; Biochemical failure; Brachytherapy; PSA bounce

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SCORING SYSTEM; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; MICHIGAN; MIDDLE AGED; NEOADJUVANT THERAPY; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77949656533     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2009.07.005     Document Type: Article

References (31)

1. Wallner K.E., Blasko J., and Dattoli M.J. Evaluating cancer status. In: Wallner K.E., Blasko J., and Dattoli M.J. (Eds). Prostate brachytherapy made complicated (1997), SmartMedicine Press, Seattle 14-15
2. Critz F.A., Williams W.H., Benton J.B., et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163 (2000) 1085-1089
3. Morita M., Lederer J.L., Fukagai T., et al. PSA bounce phenomenon after transperineal interstitial permanent prostate brachytherapy for localized prostate cancer. Nippon Hinyokika Gakkai Zasshi 95 (2004) 609-615
4. Das P., Chen M.H., Valentine K., et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys 54 (2002) 698-702
5. Cavanagh W., Blasko J.C., Grimm P.D., et al. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 18 (2000) 160-165
6. Crawford III E.D., Mackenzie S.H., Safford H.R., et al. The effect of bicycle riding on serum prostate specific antigen levels. J Urol 156 (1996) 103-105
7. Critz F.A., Williams W.H., Levinson A.K., et al. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: The relationship to patient age. J Urol 170 (2003) 1864-1867
8. Stock R.G., Stone N.N., and Cesaretti J.A. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: Descriptions and implications. Int J Radiat Oncol Biol Phys 56 (2003) 448-453
9. Toledano A., Chauvenic L., Flam T., et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: A study of 295 patients with a minimum 3-year follow up. Brachytherapy 5 (2006) 122-126
10. Merrick G.S., Butler W.M., Wallner K.E., et al. Prostate-specific antigen (PSA) spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 54 (2002) 450-456
11. Patel C., Elshaikh M.A., Angermeier K., et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 63 (2004) 110-113
12. Bostancic C., Merrick G.S., Butler W.M., et al. Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 68 (2007) 1431-1437
13. Horwitz E.M., Levy L.B., Martinez A.A., et al. The post-treatment PSA bounce for prostate cancer patients treated with external beam RT or permanent brachytherapy alone is not biochemically or clinically significant: A multi-institutional pooled analysis of more than 7500 patients. Int J Radiat Oncol Biol Phys 66 (2006) S205
14. Crook J., Gillan C., Yeung I., et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 69 (2007) 426-433
15. Ciezki J.P., Reddy C.A., Garcia J., et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 64 (2006) 512-517
16. Zietman A.L., Christodouleas J.P., and Shipley W.U. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: Impact on definitions of failure. Int J Radiat Oncol Biol Phys 62 (2005) 714-718
17. Horwitz E.M., Levy L.B., Thames H.D., et al. Biochemical and clinical significance of posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: A multiinstitutional pooled analysis. Cancer 107 (2006) 1496-1502
18. Hanlon A.L., Pinover W.H., Horwitz E.M., et al. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 50 (2001) 845-849
19. Feigenberg S.J., Hanlon A.L., Horwitz E.M., et al. A prostate specific antigen (PSA) bounce greater than 1.4 ng/ml is clinically significant after external beam radiotherapy for prostate cancer. Am J Clin Oncol 29 (2006) 458-462
20. Sengoz M., Abacioglu U., Cetin I., et al. PSA bouncing after external beam radiation for prostate cancer with or without hormonal treatment. Eur Urol 43 (2003) 473-477
21. Rosser C.J., Kamat A.M., Wang X., et al. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?. Urology 66 (2005) 327-331
22. Pruthi R.S. Editorial: Re. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 164 (2000) 2031
23. Vargas C.E., Martinez A.A., Boike T.P., et al. High dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 66 (2006) 416-423
24. Consensus statement: Guidelines for PSA following radiation therapy. American Society of Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
25. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
26. Pickles T., and British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 69 (2007) 426-433
27. Demanes D.J., Rodriquez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61 (2005) 1306-1316
28. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055
29. Martinez A.A., Gustafson G., Gonzalez J., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 316-327
30. Prestigiacomo A.F., and Stamey T.A. A physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/ml range in male volunteers. J Urol 155 (1996) 1977-1980
31. Abramowitz M.C., Li T., Buyyounouski M.K., et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112 (2008) 55-60